Skip to main content

Advertisement

Table 2 Adherence to PEG-IFN and RBV among the overall population, those on 12 weeks of therapy, and those on 24 weeks of therapy

From: Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

Variable Overall (n = 93) 12 week (n = 61) 24 week (n = 26)
Treatment completion 71 (76) 59 (97) 12 (46)
Mean on-treatment PEG-IFN adherence percent, (SD) 98.2 (4.5) 98.5 (3.1) 98.7 (3.0)
Mean on-treatment ribavirin adherence percent, (SD) 94.6 (8.8) 94.8 (8.1) 94.1 (10.8)
Missed doses of PEG-IFN, n (%)
 No missed doses 87 (94) 59 (97) 22 (85)
 1 missed dose 6 (6) 2 (3) 4 (15)
 2–5 missed doses 0 (0) 0 (0) 0 (0)
  > 5 missed doses 0 (0) 0 (0) 0 (0)
Missed doses of ribavirin, n (%)
 100% of doses taken 22 (25) 16 (26) 5 (20)
 95%- < 100% of doses taken 38 (44) 25 (41) 13 (52)
 90%- < 95% of doses taken 15 (17) 11 (18) 4 (16)
 80%- < 90% of doses taken 7 (8) 6 (10) 1 (4)
  < 80% of doses taken 5 (6) 3 (5) 2 (8)
Number of weeks of PEG-IFN therapy, n (%)
 24 weeks 12 (13) NA 12 (46)
 13 to 23 weeks 3 (3) NA 3 (3)
 7 to 12 weeks 69 (74) 61 (100) 8 (31)
 0 to 6 weeks 9 (10) 0 (0) 3 (12)
Weeks on PEG-IFN therapy
 Mean, n (SD) NA 11.9 (0.65) 16.8 (7.8)
 Median, n (IQR) NA 12 (12–12) 21 (10–24)
PEG-IFN dose-modification 9 (10) 3 (5) 6 (23)
Ribavirin dose-modification 21 (23) 12 (20) 9 (35)